Full Press Release Details
Lexaria Bioscience Corp. Receives New U.S. Patent Allowance
Delivery and Updates its Expanding Patent Portfolio
Kelowna, British Columbia April 11, 2018 Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ), a drug delivery
platform innovator, announces it has received another new Notice of Allowance
from the United States Patent and Trademark Office ( USPTO ) providing claims
that protect processes for making specific compositions of matter for enhanced
cannabinoid delivery utilizing its DehydraTECH technology. This follows
Lexaria s March 22, 2018 press release announcing receipt of the Notice of
Allowance for the compositions of matter. These two Notices of Allowance are
expected to become Lexaria s 3rd and 4th granted patents
Lexaria s DehydraTECH intellectual property portfolio has
expanded greatly and now consists of a wide variety of patent families with
multiple applications within. Patent applications span compositions and related
methods of manufacture and use for Lexaria s DehydraTECH technology with a
broad range of lipophilic active substances in foods, beverages, and nutritional
supplements, as well as in topical preparations and pharmaceutical dosage forms.
The first patent family is Food and Beverage Compositions
Infused With Lipophilic Active Agents and Methods of Use Thereof , under which
two US patents have been granted, two US patents have been allowed, and multiple
patent applications remain pending. Numerous national phase applications have
also been filed under the International Patent Cooperation Treaty ( PCT ). One
Australian patent has been granted and patent applications are pending in
Australia, Canada, China, the European Union, India, and Japan. Original filing
dates for this family begin in 2014.
The second patent family is Methods for Formulating Orally
Ingestible Compositions Comprising Lipophilic Active Agents , under which a US
provisional patent application was filed and a PCT filing was based thereon.
There is currently one patent application pending in each of the US, Australia,
Canada, China, the EU, India, and Japan. Original filing dates for this family
The third patent family is Stable Ready-to-Drink Beverage
Compositions Comprising Lipophilic Active Agents , under which a US provisional
patent application was filed and a PCT filing was based thereon. There is
currently one patent application pending in each of the US, Australia, Canada,
China, the EU, India, and Japan. Original filing dates for this family begin in
The fourth patent family is Microwave Processing Methods for
Formulating Orally Ingestible Compositions Comprising Lipophilic Active Agents ,
under which one US provisional patent application is pending and a PCT filing is
planned. Original filing dates for this family begin in 2017.
The fifth patent family is Food and Beverage Compositions
Comprising PDE5 Inhibitors , under which one US provisional patent application
is pending and a PCT filing is planned. Original filing dates for this family
The sixth patent family is Transdermal Delivery of Lipophilic
Active Agents , under which one US provisional patent application is pending and
a PCT filing is planned. Original filing dates for this family begin in 2018.
Lexaria is now managing a portfolio of more than 35 patent
applications in over 40 countries around the world and will continue to develop
and strengthen its patent portfolio in the USA, Canada, and internationally. New
patent application filings for new patent families are planned during 2018 and
Lexaria also expects further patent awards this year. As its patent portfolio
expands, Lexaria will be better able to commercialize its technologies and
defend its intellectual property.
Lexaria s patented DehydraTECH technology is focused on
improved delivery methodologies of many commonly used active
pharmaceutical ingredient ( API ) substances. As such, it provides an additional
layer of effectiveness that is designed to harmonize with the intellectual
property of third parties. Both patented and generic API substances can utilize
Lexaria s patented technology. Lexaria s long term strategy is to partner with
the world s leading firms as they deliver best-of-class products to their
existing large consumer groups.
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria s
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)
and on Facebook http://tinyurl.com/y8vzcaam
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the Company's
public announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance the Company will be capable of developing,
marketing, licensing, or selling edible products containing cannabinoids or any